enGene Named a BioSpace 2026 Best Places to Work Winner
enGene Holdings Inc. (ENGN)
Company Research
Source: Business Wire
enGene selected for its innovation in advancing non-viral genetic medicines and fostering a culture of collaboration and purposeSelection follows BIOTECanada’s 2025 Biotech Company of the Year award BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (“enGene” or the “Company”) (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, today announced that BioSpace has named the company to its 2026 Best Places to Work. enGene is among 50 U.S. operating employers recognized as one of the most desirable workplaces in the life sciences industry.“Recognition as a BioSpace Best Place to Work honors enGene’s commitment to create a positive work environment, underpinned by our mission to deliver non-viral medicines to improve the lives of people with urological cancers,” said Ron Cooper, President and Chief Executive Officer, enGene. “We are bringing our mission to life by advancing our late-stage clinical asset, detalimogene, for patients with an early form of bladder ca
Show less
Read more
Impact Snapshot
Event Time:
ENGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENGN alerts
High impacting enGene Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ENGN
News
- enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial [Yahoo! Finance]Yahoo! Finance
- enGene (NASDAQ:ENGN) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing ReadinessBusiness Wire
- enGene to Present at the Piper Sandler 37th Annual Healthcare ConferenceBusiness Wire
- enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded WarrantsBusiness Wire
ENGN
Sec Filings
- 11/18/25 - Form SCHEDULE
- 11/18/25 - Form SCHEDULE
- 11/14/25 - Form 8-K
- ENGN's page on the SEC website